AVIANE 21 TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
15-03-2019
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
LEVONORGESTREL; ETHINYL ESTRADIOL
Tilgjengelig fra:
TEVA CANADA LIMITED
ATC-kode:
G03AA07
INN (International Name):
LEVONORGESTREL AND ESTROGEN
Dosering :
100MCG; 20MCG
Legemiddelform:
TABLET
Sammensetning:
LEVONORGESTREL 100MCG; ETHINYL ESTRADIOL 20MCG
Administreringsrute:
ORAL
Enheter i pakken:
21
Resept typen:
Prescription
Terapeutisk område:
CONTRACEPTIVES
Produkt oppsummering:
Active ingredient group (AIG) number: 0220415005; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2007-08-17
Preparatomtale
PRODUCT
MONOGRAPH
Pr
AVIANE
® 21 AND
Pr
AVIANE
® 28
Levonorgestrel and Ethinyl Estradiol
Tablets, 0.10 mg levonorgestrel, 0.02 mg ethinyl estradiol
USP
Oral Contraceptive
G03AA07
Teva Canada Limited
30 Novopharm Court
Toronto, ON M1B 2K9
Date of Revision:
March 15, 2019
Submission Control No: 225099
_ _
_ _
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
25
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 29
STORAGE AND STABILITY
.........................................................................................
30
SPECIAL HANDLING INSTRUCTIONS
......................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 30
PART II: SCIENTIFIC INFORMATION
...............................................................................
31
PHARMACEUTICAL INFORMATION
.........................................................................
31
CLINICAL TRIALS
.........................................................................................................
33
ORAL CONTRACEPTION
.............................................................................................
34
DETAILED PHARMACOLOGY
......................................................
Les hele dokumentet
